JBIO.OQ - Jade Biosciences Inc
Guggenheim Securities LLCEstimate Increase, Price Target Increase
JBIO: Raising JADE101 POS to 55% and Increasing PT to $23 (from $17) Given Continued Mechanism Validation; Reiterate Buy Rating Ahead of Phase 1 Data in 2Q26; 4Q25 Recap
公司
JBIO.OQ
日期
2026-03-10
分析师
Mr. Vamil K. Divan, MD
页数
5 页
需要登录
请登录后购买研报或生成音频内容。